JCR Pharmaceuticals (OTCMKTS:JCRRF – Get Free Report) is projected to release its results after the market closes on Thursday, October 29th. Analysts expect JCR Pharmaceuticals to post earnings of $0.0011 per share and revenue of $80.16 million for the quarter.
JCR Pharmaceuticals Price Performance
JCR Pharmaceuticals stock opened at $3.73 on Tuesday. The stock’s 50 day simple moving average is $3.46 and its two-hundred day simple moving average is $3.79. JCR Pharmaceuticals has a fifty-two week low of $3.15 and a fifty-two week high of $3.73.
About JCR Pharmaceuticals
JCR Pharmaceuticals Co, Ltd. is a Japan-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company’s research programs include biologics, enzyme replacement therapies, growth hormone products, and regenerative medicine, with an emphasis on applying biotechnology to improve patient care.
JCR’s portfolio includes therapies for rare lysosomal storage disorders and pediatric diseases.
See Also
- Five stocks we like better than JCR Pharmaceuticals
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for JCR Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JCR Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
